Chen Yu jumps ship from Vi­vo Cap­i­tal and goes large, al­ly­ing with The Col­umn Group on an in­au­gur­al $824M biotech crossover fund

Over the past 15 years, the crew at The Col­umn Group have gath­ered more than $2 bil­lion to­geth­er to pur­sue their game plan of fos­ter­ing biotech star­tups. And it’s been ef­fec­tive. Their port­fo­lio plays have pro­vid­ed a tar­get-rich en­vi­ron­ment for big play­ers like Roche and J&J and Ver­tex to come stalk­ing ac­qui­si­tions.

Re­cent­ly, though, one of the man­ag­ing part­ners at Vi­vo Cap­i­tal jumped ship af­ter a very long tenure — 17 years — and went on to quick­ly cre­ate a brand new biotech fund they’re part­nered with the VC on called TCG Crossover; TCG X in ab­bre­vi­at­ed fash­ion. His name is Chen Yu, and in the midst of the busiest crossover sea­son in the in­dus­try’s his­to­ry, he’s jump­ing in to the game with an $824 mil­lion stake that will be put in­to play at the junc­tion in­ter­sect­ing biotechs with pub­lic mar­kets — with a spe­cial side fo­cus on the boom­ing Chi­na mar­ket, where he’s been a play­er for years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER